Patents by Inventor Morten Persson

Morten Persson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING
    Publication number: 20220202966
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Application
    Filed: March 17, 2022
    Publication date: June 30, 2022
    Applicant: CURASIGHT A/S
    Inventors: Andreas KJAER, Morten PERSSON, Jacob MADSEN
  • Positron emitting radionuclide labeled peptides for human uPAR PET imaging
    Patent number: 11311637
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: April 26, 2022
    Assignee: Curasight A/S
    Inventors: Andreas Kjaer, Morten Persson, Jacob Madsen
  • 177-Lu LABELED PEPTIDE FOR SITE-SPECIFIC uPAR-TARGETING
    Publication number: 20210236666
    Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
    Type: Application
    Filed: January 7, 2021
    Publication date: August 5, 2021
    Applicant: RIGSHOSPITALET
    Inventors: Andreas KJAER, Morten PERSSON, Michael PLOUG
  • uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
    Publication number: 20210138090
    Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 13, 2021
    Applicant: FLUOGUIDE A/S
    Inventors: Andreas KJAER, Morten PERSSON, Karina JUHL, Sorel KURBEGOVIC, Michael PLOUG, Knud Jørgen JENSEN, Kasper Kildegaard SØRENSEN, Anders CHRISTENSEN, Line HARTVIG, Grethe Nørskov RASMUSSEN, Morten ALBRECHTSEN
  • 177-Lu labeled peptide for site-specific uPAR-targeting
    Patent number: 10994032
    Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: May 4, 2021
    Assignee: TRT Innovations APS
    Inventors: Andreas Kjaer, Morten Persson, Michael Ploug
  • POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING
    Publication number: 20200268914
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Applicant: CURASIGHT APS
    Inventors: Andreas KJAER, Morten PERSSON, Jacob MADSEN
  • UPAR TARGETING PEPTIDE FOR USE IN PEROPERATIVE OPTICAL IMAGING OF INVASIVE CANCER
    Publication number: 20190125903
    Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.
    Type: Application
    Filed: September 26, 2018
    Publication date: May 2, 2019
    Applicant: RIGSHOSPITALET
    Inventors: Andreas KJAER, Morten PERSSON
  • uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
    Patent number: 10111969
    Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: October 30, 2018
    Assignee: RIGSHOSPITALET
    Inventors: Andreas Kjaer, Morten Persson
  • POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING
    Publication number: 20180193495
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 12, 2018
    Inventors: Andreas Kjaer, Morten Persson, Jacob Madsen
  • Positron emitting radionuclide labeled peptides for human uPAR PET imaging
    Patent number: 9884131
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: February 6, 2018
    Assignee: CURASIGHT APS
    Inventors: Andreas Kjaer, Morten Persson, Jacob Madsen
  • UPAR TARGETING PEPTIDE FOR USE IN PEROPERATIVE OPTICAL IMAGING OF INVASIVE CANCER
    Publication number: 20170304468
    Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 26, 2017
    Inventors: Andreas KJAER, Morten PERSSON
  • POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING
    Publication number: 20160263260
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Application
    Filed: November 29, 2013
    Publication date: September 15, 2016
    Inventors: Andreas KJAER, Morten PERSSON, Jacob MADSEN
  • 177-Lu LABELED PEPTIDE FOR SITE-SPECIFIC uPAR-TARGETING
    Publication number: 20150132219
    Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 14, 2015
    Inventors: Andreas Kjaer, Morten Persson, Michael Ploug